Metastases

The effect of PSA doubling time (PSADT) and Gleason score on the PSA at the time of initial metastasis in men with biochemical recurrence after prostatectomy.

The researchers took a cohort of 430 men with a biochemical recurrence (PSA increase only) after failed prostatectomy. The men underwent observation until they experienced metastatic disease as determined by CT or bone scan. The researchers then evaluated the PSA at the time the men developed metastasis for those patients who developed metastatic disease. PSA [...]

By Malecare|2017-10-19T10:53:17-04:00February 17th, 2011|Advanced Prostate Cancer, General Information, Metastases, Research, Uncategorized, Understanding APC|2 Comments

Long-Term Overall Survival & Metastasis-Free Survival Post Surgery After A Biochemical Recurrence of Prostate Cancer

Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]

By Malecare|2017-10-19T10:53:22-04:00January 4th, 2011|Advanced Prostate Cancer, Drugs & Treatments, General Information, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Zoledronic Acid Therapy Impacts Risk and Frequency of Skeletal Complications In Men with Prostate Cancer – Start Early Therapy

To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]

By Malecare|2010-12-28T11:32:31-05:00December 28th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Research, Uncategorized, Understanding APC, Zometa|1 Comment

Disease and Host Characteristics as Predictors of Time to First Bone Metastasis and Death in Men with Castration Resistant Nonmetastatic Prostate Cancer

Researchers at the Department of Hematology-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts performed an evaluation of the natural history of castration-resistant non-metastatic prostate cancer. For their analysis, the researchers used data from 331 subjects in a placebo group of a randomized controlled trial to evaluate the relations of disease and host characteristics with time [...]

By Malecare|2017-10-19T10:53:23-04:00December 27th, 2010|Advanced Prostate Cancer, General Information, Metastases, Research, Uncategorized, Understanding APC|0 Comments

Zoledronic Acid Shows Improved Clinical Outcomes When Administered Prior to Bone Pain in Men with Advanced Prostate Cancer

According to the FDA approval label, zoledronic acid (Zometa) should be administered to men with advanced prostate cancer once they have failed one hormone therapy type, in other words, once the cancer has become castrate resistant. Researchers at the Centre Hospitalier de i’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada evaluated the effect of zoledronic [...]

By Malecare|2017-10-19T10:53:24-04:00December 15th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Uncategorized, Understanding APC, Zometa|2 Comments

Denosumab delays the Spread of Prostate Cancer to the Bones, But it Doesn’t Extend Life!

Results from a recent clinical trial indicate that denosumab delayed the spread of prostate cancer metastases bones, however it did not prolong the lives of men. […]

By Malecare|2017-10-19T10:53:24-04:00December 14th, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, denosumab - Prolia, Drugs & Treatments, General Information, Metastases, Uncategorized, Understanding APC|0 Comments

Malecare’s Advanced Prostate Cancer Program

Malecare is pleased to announce several new enhancements to our Advanced Prostate Cancer Program as well as the release of our new Advanced Prostate Cancer Kit which includes our newest publication: RECURRENT PROSTATE CANCER A Working Document for Men with Recurrent Prostate Cancer For many years, Malecare has been the leader in the fight against [...]

Xgeya (denosumb) Approved To Protect Bones In Men With Metastatic Prostate Cancer

This has been an interesting year as men with advanced prostate cancer have seen three different drugs approved. Considering that the prior six years did not have any new drug approvals, this has been a stellar year. First we had Provenge approved, then came Jevtana and now we have added to the list Xgeya (denosumb). [...]

By Malecare|2010-12-02T12:10:18-05:00December 2nd, 2010|Advanced Prostate Cancer, bisphosphonates, denosumab - Prolia, Drugs & Treatments, Metastases, Research, Uncategorized|1 Comment

On The Horizon- XL 184 Shows Remarkable and Surprising Results In A Small & Early Trial

Although some people have called it intriguing, a new “On The Horizon” drug, XL-184, is still very early in its testing. What makes LX184 intriguing is the just released results from a conference in Berlin. In very early testing, 19 of 20 men in a phase I trial showed an improvement in their scans used [...]

By Malecare|2020-02-04T11:07:53-05:00November 23rd, 2010|Advanced Prostate Cancer, Clinical Trials, Clinical Trials, Drugs & Treatments, LX184, Metastases, On The Horizon, Research, Uncategorized|1 Comment

From the 2010 AUA Conference

For men with advanced prostate cancer adjuvant radiation therapy improves the cancer-specific survival of men with seminal vesicle invasion, even in the presence of nodal metastases. This underscores the need for multi-modal treatment approaches in advanced prostate cancer patients. Joel T. Nowak, M.A., M.S.W.

By Malecare|2017-10-19T10:53:41-04:00September 13th, 2010|Advanced Prostate Cancer, Drugs & Treatments, Metastases, Radiotherapy, Uncategorized, Understanding APC|0 Comments